Article
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.
Expert review of hematology - 1 Jun 2024
Bruzzese Antonella, Vigna Ernesto, Martino Enrica Antonia, Labanca Caterina, Mendicino Francesco, Lucia Eugenio, Olivito Virginia, Stanzione Gaia, Zimbo Annamaria, Lugli Elisabetta, Neri Antonino, Morabito Fortunato, Gentile Massimo
Abstract excerpt
INTRODUCTION: Acute myeloid leukemia (AML) encompasses a heterogeneous group of aggressive myeloid malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent, accounting for approximately 25-30% of adult patients. The presence of this mutation is related to a dismal prognosis and high relapse rates. In the lasts years many FLT3 inhibitors have been developed. AREAS COVERED: This review provides...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Antineoplastic Combined Chemotherapy Protocols
- Mutation
- Protein Kinase Inhibitors
- Drug Resistance, Neoplasm
- Staurosporine
- Treatment Outcome